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Abstract
Rationale
Inhaled nitric oxide (NO) exerts a variety of effects through metabolites and these play an
important role in regulation of hemodynamics in the body. A detailed investigation into the
generation of these metabolites has been overlooked.
Objectives
We investigated the kinetics of nitrite and S-nitrosothiol-hemoglobin (SNO-Hb) in plasma
derived from inhaled NO subjects and how this modifies the cutaneous microvascular
response.
Findings
We enrolled 15 healthy volunteers. Plasma nitrite levels at baseline and during NO inhala-
tion (15 minutes at 40 ppm) were 102 (86–118) and 114 (87–129) nM, respectively. The
nitrite peak occurred at 5 minutes of discontinuing NO (131 (104–170) nM). Plasma nitrate
levels were not significantly different during the study. SNO-Hb molar ratio levels at baseline
and during NO inhalation were 4.7E-3 (2.5E-3–5.8E-3) and 7.8E-3 (4.1E-3-13.0E-3),
respectively. Levels of SNO-Hb continued to climb up to the last study time point (30 min:
10.6E-3 (5.3E-3-15.5E-3)). The response to acetylcholine iontophoresis both before and
during NO inhalation was inversely associated with the SNO-Hb level (r: -0.57, p = 0.03, and
r: -0.54, p = 0.04, respectively).
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Conclusions
Both nitrite and SNO-Hb increase during NO inhalation. Nitrite increases first, followed by a
more sustained increase in Hb-SNO. Nitrite and Hb-SNO could be a mobile reservoir of NO
with potential implications on the systemic microvasculature.
Introduction
Over the past years the role of NO in biology has increased tremendously and is involved in
diverse functions such as bacterial defense, neurotransmission and reproduction [1–4]. NO is
a highly diffusible gas synthesized by a group of nitric oxide synthases (NOS) [5]. It was identi-
fied in 1980s and initially referred as endothelium-dependent relaxation factor [6–8]. Three
isoforms of NOS exist but the endothelial NOS (type 3 NOS) generates NO in the pulmonary
vascular bed [9]. Upon generation, NO diffuses to adjacent cells [10]. NO’s half-life can be as
low as 1.8 ms in the presence of mM concentrations of hemoglobin (Hb) [8, 11, 12], and there-
fore it is likely not the principal effector molecule for many NO bioactivities. NO can be rap-
idly oxidized to nitrate (NO3
-) and nitrite (NO2
-) [13], or taken by hemoglobin (Hb) to form
nitrosyl-Hb (Hb:[Fe]NO) or S-nitrosothiol-Hb (SNO-Hb) [14].
NO administered via inhalation relaxes the pulmonary vasculature. Inhaled NO in criti-
cally ill neonates with pulmonary hypertension improves oxygenation [15, 16] and is cur-
rently approved by the US Food and Drug Administration [17, 18] for treatment of term and
near-term neonates with hypoxic respiratory failure associated with clinical or echocardio-
graphic evidence of pulmonary hypertension. Other studies have suggested that inhaled NO
could be used to treat a wide spectrum of cardiopulmonary conditions, including acute
respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease (COPD),
acute pulmonary embolism (PE), hypoxemic respiratory failure and pulmonary hyperten-
sion [19–23].
Inhaled, NO diffuses across the lung, reaching the smooth muscle cells of subjacent ves-
sels where it causes selective pulmonary vasodilation [24, 25]. Besides local pulmonary
effects, mounting evidence supports that inhaled NO exerts a variety of systemic effects. A
number of studies have demonstrated that inhaled NO can affect multiple organs [26–35].
Indeed inhaled NO can be protective in brain injury as demonstrated by the hypoxia-ische-
mia or traumatic brain injury models [30–35]. Given the efficient scavenging by hemoglo-
bin, the systemic effects are unlikely caused by direct effects of the inhaled NO itself [5].
Nitrite, low molecular weight SNO (eg. S-Nitrosoglutathione (GSNO)) or protein bound
SNO species, may be involved in transporting the NO signal to the systemic circulation
[36]. In fact, during hypoxic conditions, nitrite can regenerate NO by nitrite reductases
[37, 38] and SNO-Hb is bioactivated by transfering nitrosonium (NO+) to other thiols [14,
39].
Controversy persists on whether both nitrite in plasma and SNO-Hb in erythrocytes
increase during NO inhalation [40]. In fact, there remains a need for a quantitative evaluation
of the array of circulating NO metabolites generated by breathing NO and the fate of these
metabolites after ceasing its administration. Furthermore, little is known whether inhaled NO
affects the cutaneous microcirculation. We hypothesized that inhaled NO increases the plasma
levels of nitrite and SNO-Hb which then modify the cutaneous microvascular response to
vasoactive mediators that challenge the NO pathway.
Nitric oxide metabolites in healthy subjects
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Materials and methods
a) Study approval
The study was approved by the institutional review board of the Cleveland Clinic (IRB # 12–
1328). All subjects provided written informed consent prior to inclusion in the study. We con-
ducted this cross-sectional study between May 2015 and September 2015.
b) Subject selection and environment
Volunteers were in excellent general health and underwent a detailed evaluation to rule out
smoking or conditions (e.g. diabetes, hypercholesterolemia or hypertension) that could affect
the NO metabolism or cutaneous microcirculation. Subjects did not eat or drink for 4 hours
prior to testing. Procedures were performed in a private room where individuals were acclima-
tized for at least 30 minutes (room temperature: 72˚ F or 22˚ C).
c) Nitric oxide inhalation
Nitric oxide (INOMAX, Mallinckrodt Pharmaceuticals, Hazelwood, MO, USA) was adminis-
tered continuously for 15 minutes through a disposable nasal cannula at a dose of 40 ppm, car-
ried by room air at a flow rate of 4 L/min, following manufacturer’s recommendations.
d) Laboratory determinations
-Blood collection. We placed a temporary venous access in the dorsal aspect of the right
hand. Blood was obtained at baseline (before NO inhalation), at 15 minutes of continuous NO
administration and at 5, 15 and 30 minutes of stopping this gas supplementation. Blood was
collected using heparin vacutainer tubes (BD Biosciences, NJ, USA) and immediately centri-
fuged for 3 minutes to separate plasma from red blood cells (RBC). Without any delay, both
plasma and RBC samples were frozen using liquid nitrogen, to preserve the NO metabolites.
Samples were stored at -80˚ Celsius until assayed. Samples for analysis were only thawed once
and the remainder discarded. No detectable nitrite was observed in the heparin vacutainer
tubes or in sample storage tubes. All precautions were taken to minimize nitrite loss during
the freezing / thawing procedure [41]. In addition, we tested the stability of nitrite levels during
the freezing / thawing procedure by measuring nitrite before freezing and after snap freezing
and thawing from a single individual and noted only a small variation in the nitrite concentra-
tion (fresh sample: 100.1 +2.6 nM and thawed sample: 101.4 +/- 4.8 nM (S1 Table)).
-Nitrite and nitrate determinations in plasma. Samples were deproteinated using metha-
nol precipitation. Immediately after thawing the plasma samples, two volumes of methanol
were added, and samples kept at -20˚ Celsius for at least 15 minutes to allow protein precipita-
tion. Samples were then spun down to remove the precipitated proteins. The supernatant was
then used for subsequent analyses. Nitrite was measured using ozone-based chemiluminescence
with the triiodide method and Sievers NO analyzer (GE Analytical Instruments, Boulder, CO,
USA) [42–44]. Briefly, the triiodide reagent was made using 1g of KCI and 0.65 g of iodine dis-
solved in 20 ml of distilled water, with the addition of 70 ml of acetic acid. A total of 6 ml of this
solution was used in the reaction chamber for nitrite conversion into NO. A standard curve was
generated using up to 500 nM of nitrite. We used 200ul aliquots of the sample to inject into the
reaction chamber. Since the volume of the reaction chamber would alter over time, we limited
the number of injections but kept the samples from each subject together. At the beginning
with each fresh reagent in the reaction chamber, we ran a standard and one after the last sample.
The levels of these standards were similar and so suggested the reagent was still sufficiently
active. A similar method was used for detection of nitrate, with the only difference that the
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reagent was a saturated solution of vanadium (III) chloride (0.6 g in 100 ml of 1N HCl), heated
to 94˚ C [45, 46]. A standard curve was generated using nitrate up to 25 uM.
-SNO-Hb and Hb:[Fe]NO measurement in RBCs. RBC samples were assayed for total, Fe-
bound and thiol-bound NO (SNO) content by photolysis/chemiluminescence, as described previ-
ously [47, 48]. Briefly, samples were thawed (2 min, 37C), fully lysed (addition of ddH2O/vortex),
and centrifuged (25,000 g, 5 min, 4C) to remove cell debris and membrane. Supernatant was run
through a Sephadex G25 spin column, following which [Hb] was measured [49]. To selectively
remove thiol bound NO (SNO), samples were incubated ±HgCl2 (6 fold molar excess over [Hb
thiol]; tetramer basis)[50, 51]. Following this minimal processing, samples were injected into an
HPLC pump (Analytical Scientific Instruments, Richmond, CA) purged with degassed, deionized
water as the mobile phase, and carried (1 ml/min) to a custom photolysis system (Technosoft, Mor-
risville, NC, USA) comprising a quartz coil looped around a mercury arc lamp (Hanovia, Inc., New-
ark, NJ). This photolytically liberates bound NO, that is then subsequently carried in an inert gas
stream (helium), to a high-resolution chemiluminescence NO analyzer (TEA 810, Ellutia, Charles-
ton, SC, USA). Aqueous phase and higher oxides of nitrogen were removed in a series of cold traps
interposed between the photolysis and analyzer units. A GSNO standard curve was performed each
day with analysis of sample area under curve (Clarity, Madison, CT). Unknown sample areas were
read off the standard curve, to determine NO content. Total NO content was derived from vehicle
incubated sample. Fe-NO was obtained from the sample incubated with HgCl2. SNO-Hb was calcu-
lated from the difference between these two signals. Measurements of RBC NO are presented as a
molar ratio of NO to Hb. Determinations were done in duplicate and an average reported [47, 48].
-Bicarbonate determination. Bicarbonate was measured using a Bicarbonate reagent kit
on a Cobas C501 analyzer (Roche Diagnostics, Indianapolis, IN). Briefly, phosphoenolpyr-
uvate in the presence of phosphoenolpyruvate carboxylase to produces oxaloacetate and phos-
phate. The oxaloacetate produced is coupled with NADH in the presence of malate
dehydrogenase to produce malate and NAD. The consumption of NADH is measured 320 nm
to 400 nm and the bicarbonate concentration determined.
-Cutaneous microvascular studies. Subjects were tested in a sitting position with the fore-
arm at the level of the heart. We measured the subjects’ heart rate, blood pressure, and pulse oxy-
gen saturation. We carefully prepped the skin of the anterior aspect of the forearm, 5 cm distal to
the antecubital fossa and away from visible veins or skin abrasion [52]. Great care was taken to
create similar experimental conditions to ensure regional and temporal reproducibility.
a) Skin microvascular flow
We estimated the skin microvascular flow during the last minute of NO inhalation and for 5
minutes after its discontinuation, using Laser Doppler flowmetry [53] with the PeriFlux system
5000 (Perimed, Ja¨rfa¨lla, Sweden) and an integrating probe (PF 413) [54]. We continuously
recorded data from the instrument for off-line review, using the PeriSoft for Windows soft-
ware. Flow measurements are expressed as arbitrary perfusion units (PU) averaged over 30
seconds of recording. Probes were calibrated using a motility standard consisting of a colloidal
suspension of polystyrene particles (PF 1000). Laser Doppler flowmetry assesses the skin capil-
lary perfusion (depth of skin penetration of about 1mm) by measuring the Doppler shift
induced by the laser light scattering of moving red blood cells. Perfusion is defined as the con-
centration of red blood cells times their average velocity [55, 56].
b) Iontophoresis of acetylcholine and sodium nitroprusside
Iontophoresis was performed using the thermostatic probe PF 481, the periIont micropharma-
cology system, the drug delivery electrodes PF 383 and the dispersive electrodes PF 384
Nitric oxide metabolites in healthy subjects
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(Perimed, Ja¨rfa¨lla, Sweden) [52]. At different skin sites, we placed 180 μL of either acetylcho-
line 1% (Sigma-Aldrich, St Louis, MO, USA) or sodium nitroprusside 1% (Marathon Pharma-
ceuticals, LLC, Northbrook, IL, USA) in the sponge of the drug-delivery electrode. We
iontophoresed these agents at 40 uA for 5 minutes. We used a positive polarity for acetylcho-
line and negative polarity for sodium nitroprusside. Both tests were performed before and dur-
ing NO administration (at minutes 5 and 9 for acetylcholine and sodium nitroprusside,
respectively). Current-induced vasodilation was prevented by limiting the current density
to< 0.01 mA/cm2 [57]. During each test, we measured changes in PU and monitored skin
resistance and temperature. Skin resistance was determined by the periIont micropharmacol-
ogy system and recorded before and during the iontophoresis of medications, since variations
in the skin resistance may affect the current flow and the transport of vasoactive mediators.
We believe that the cutaneous iontophoresis of vasoactive agents has not affected the levels
of NO metabolites, given its local effect, low dose and the fact that blood was obtained in the
opposite arm. Additionally, we have previously shown that using our methodology levels of
iontophoresed agents are not detectable in blood [52].
Statistics
Continuous data are presented as median (interquartile range (IQR)). Categorical data are
summarized as discrete values and percentages (n (%)). Results of the iontophoresis tests are
expressed as peak PUs or percentage of variation from baseline. Independent continuous sam-
ples were compared using Wilcoxon-Mann-Whitney test. Paired continuous samples were
tested with Wilcoxon signed-rank test and Bonferroni correction. We tested repeated mea-
surements with the nonparametric Friedman test. Relationships between normally distributed
variables were assessed using the Spearman rank correlation coefficient. All p values are two-
tailed and a value of< 0.05 was considered significant. The statistical analyses were performed
using the statistical package IBM SPSS, version 20 (IBM; Armonk, New York) and MedCalc,
version 14.12.0 (Ostend, Belgium).
Results
a) Nitric oxide metabolites
We included 15 subjects with a median (IQR) age of 37 (31–47) years, of whom 13 (87%) were
females. We tested nitrite, nitrate, SNO-Hb and Hb:[Fe]NO before, during and after NO
administration (Table 1 and Fig 1). The basal levels of nitrite and SNO-Hb are consistent to
those found by previous investigators [48, 58–61]. The Friedman test showed significant differ-
ences among the various time points in nitrite, total RBC NO, Hb:[Fe]NO and SNO-Hb
(Table 1). We observed a significant increase in nitrite (median (IQR) difference of 7 (-2 –+19)
%, p = 0.048), total RBC NO (29 (-12 –+111) %, p = 0.02) and SNO-Hb (median (IQR) differ-
ence of 59 (-15 - +282) %, p = 0.02) during NO inhalation compared to baseline. Nitrite, total
RBC NO and SNO-Hb levels were higher 5 minutes after the discontinuation of NO compared
to baseline (28 (13–52) %, p = 0.009, 46 (3–96) %, p = 0.006, and 50 (-16 –+329) %, p = 0.03,
respectively). Interestingly, the levels of nitrite peaked at 5 minutes; meanwhile, total RBC NO
and SNO-Hb continued to increase during the 30 minutes after discontinuing NO.
b) Bicarbonate determinations
In 11 subjects we measured bicarbonate in plasma before and 30 minutes after NO inhalation.
The median (IQR) before NO inhalation and 30 minutes after discontinuation were 20.6
(19.8–23.4) and 20.5 (18.5–20.8), respectively (p = 0.04). The change in bicarbonate at 30
Nitric oxide metabolites in healthy subjects
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minutes was negatively associated with the change in SNO-Hb; however this association did
not reach statistical significance.
c) Forearm microvascular studies
The skin microvascular flow was not significantly different at baseline than during NO inhala-
tion (Table 2). During NO inhalation, compared to before NO inhalation, the peak PU
increased 62.8 (-218 - + 333.7) % points during the iontophoresis of acetylcholine and 95.8
(-123 - + 262.1) % points during the iontophoresis of sodium nitroprusside; changes that did
not achieve statistical significance (Table 2).
Before NO inhalation, the peak PU and increase in PU during acetylcholine iontophoresis
showed a negative association with the level of SNO-Hb (r: -0.57, p = 0.03 and r: -0.61,
p = 0.03, respectively). Similarly, during NO administration, the peak PU and increase in PU
during acetylcholine iontophoresis was negatively associated to the level of SNO-Hb under the
same condition (r: -0.54, p = 0.04 and r: -0.51, p = 0.05, respectively). The change in peak PU
during acetylcholine before and during NO inhalation was inversely related to the change in
SNO-Hb (r: -0.57, p = 0.03). The levels of nitrite were not significantly associated with the ace-
tylcholine iontophoresis response before or during NO administration.
Discussion
It is postulated that many of the systemic responses to inhaled NO are derived from its metab-
olites such as nitrite, S-nitrosothiols and possibly dinitrosyl iron complexes (DNICs). Both
nitrite and S-nitrosothiols can be converted back to NO to deliver this molecule to sites remote
to its generation. Nitrite can be reduced to NO by nitrite reductases and by low pH in ischemic
tissues, whereas SNO-Hb can transfer NO+ under low oxygen concentrations in the peripheral
circulation [14] (Fig 2). In the present study, we investigated how these metabolites changed
during and 30 minutes after discontinuing a 15 minute inhalation of NO. To the best of our
knowledge, the kinetics of inhaled NO increasing levels of SNO-Hb, have not been measured.
We noted that the inhalation of NO led to a significant increase in nitrite and SNO-Hb. Nitrite
peaked at 5 minutes and SNO-Hb peaked beyond 15 minutes, of discontinuing the NO
Table 1. Determinations of NO metabolites in plasma and RBC.
Baseline
Median
(IQR)
During NO
inhalation�
Median (IQR)
After 5 min of NO
discontinuation
Median (IQR)
After15 min of NO
discontinuation
Median (IQR)
After 30 min of NO
discontinuation
Median (IQR)
P (Friedman
test)
Plasma n 15 15 15 15 14^
Nitrate (uM) 25.4 (20.9–
35.0)
26.6 (21.4–35.4) 27.3 (22.8–35.3) 27.4 (20.8–33.7) 26.9 (20.2–34.3) 0.07
Nitrite (nM) 102.8 (86.3–
117.8)
114.0 (87.0–
129.0)
131.3 (104.3–169.5) 119.3 (84.8–141.8) 115.5 (105.8–127.5) <0.001
RBC Total NO (moles
NO:Hb x 10−3)
13.2 (8.0–
15.7)
15.3 (11.4–26.2) 15.2 (9.9–21.6) 18.2 (11.3–32.6) 18.7 (12.8–33.1) 0.005
NO[Fe]Hb (moles
NO:Hb x 10−3)
7.1 (3.0–
11.8)
7.1 (3.7–14.6) 9.0 (2.8–12.2) 8.2 (4.7–9.8) 8.3 (5.4–19.0) <0.001
SNO-Hb (moles
NO:Hb x 10−3)
4.7 (2.5–5.8) 7.8 (4.1–13.1) 7.3 (4.5–14.8) 10.3 (5.6–18.2) 10.6 (5.3–15.5) 0.005
�blood sample obtained at 15 minutes of continuous inhaled NO administration.
^ One patient had no blood sample 30 minutes after NO discontinuation.
Abbreviations: Hb:[Fe]NO: nitrosyl Hb, IQR interquartile range, NO: nitric oxide, O2: oxygen, SNO-Hb: S-nitrosothiol Hb.
https://doi.org/10.1371/journal.pone.0221777.t001
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inhalation. In fact, nitrite levels rapidly declined after its peak (consistent with the suggested
half-life of 30 minutes) [59, 62]; while SNO-Hb levels remained elevated for at least 30 minutes
after NO discontinuation, theoretically storing the NO signal for a longer time and possibly
increasing the minute ventilation.
Conventionally, most excess inhaled NO reacts with Fe++ Hb and oxygen to form methe-
moglobin and nitrate; the methemoglobin is then recycled by methemoglobin reductases [40,
63]. Strikingly, we did not notice a significant change in plasma nitrate during NO inhalation.
Many factors can affect nitrate levels, including diet and microbiome [64]. Inhalation of NO at
the concentration given would produce at best a small and likely non-significant change given
the inherent noise of the assay used.
Fig 1. Box plots of plasma nitrite and RBC SNO-Hb before, during and after NO inhalation. The red line connects the median values at the
different time points.
https://doi.org/10.1371/journal.pone.0221777.g001
Nitric oxide metabolites in healthy subjects
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In mice, the inhalation of NO led to increases in nitrate and nitrite in plasma as well as
SNO-Hb and Hb:[Fe]NO in erythrocytes [65], with a plateau achieved within 15 minutes of
administering NO [65]. In patients undergoing liver transplantation [66], inhaled NO pro-
duced an increase in plasma nitrate and nitrite as well as erythrocyte Hb:[Fe]NO, but not
Table 2. Forearm microvascular studies at baseline and during NO inhalation.
Variables Baseline
Median (IQR)
During NO inhalation
Median (IQR)
P (Wilcoxon signed-rank test)
Cutaneous PU 13.6 (11.8–16.8) 14.6 (9.8–20.6) 0.28
Acetylcholine iontophoresis
Baseline PU 5.6 (4.3–7.2) 4.5 (3.6–5.5) 0.33
Peak PU 49.6 (28.2–60.8) 47.4 (37.6–51.8) 0.87
Percentage change in PU 600 (420–965) 991 (363–1249) 0.57
Skin resistance 215 (175–279) 207 (165–261) 0.42
Sodium nitroprusside iontophoresis
Baseline PU 4.1 (3.6–7.6) 4.2 (2.8–5.3) 0.31
Peak PU 17.1 (10.3–21.1) 11.6 (7.1–25.9) 0.96
Percentage change in PU 190 (127–407) 231 (107–424) 0.36
Skin resistance 241 (220–251) 222 (208–272) 0.49
https://doi.org/10.1371/journal.pone.0221777.t002
Fig 2. Mechanisms by which inhaled NO acts on the systemic microcirculation. Abbreviations: Hb: hemoglobin, Hb:[Fe]NO: nitrosyl Hb, Met-Hb:
methemoglobin, NO: nitric oxide, NOS: nitric oxide synthase, O2: oxygen, ROS: reactive oxygen species, RSH: alkyl thiols, RSNO: S nitrosothiols, SNO-Hb: S-
nitrosothiol Hb, XOR: xanthine oxidoreductase.
https://doi.org/10.1371/journal.pone.0221777.g002
Nitric oxide metabolites in healthy subjects
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SNO-Hb. In contrast, our study showed an increase in SNO-Hb during NO inhalation, and
the discrepancy may be in part related to the difficulties in measuring SNO-Hb using iodine-
based methods [67], NO dosing and length of NO administration.
Initial studies suggested that the effects of inhaled NO were confined to the lungs given its
high affinity for the heme moiety of Hb [68]. Subsequent investigations, in animals, showed
that inhaled NO inhibits platelet function [69], increases glomerular filtration rate[70], reduces
neointimal formation in injured arteries [71], enhances coronary artery patency after throm-
bolysis [72], reduces myocardial infarction size [73], and maintains mesenteric blood flow in
intestinal ischemia-reperfusion injury [74]. Meanwhile, in humans, inhaled NO was noted to
reduce muscle inflammation during limb ischemia [75] and ischemia-reperfusion injury dur-
ing liver transplantation [66]. Of concern, long-term follow-up of infants exposed to inhaled
NO suggests an increased cancer risk later in childhood [27]. Nitric oxide itself can be muta-
genic, but most authors argue that NO radical is not present in any relevant concentration in
the presence of mM vascular concentrations of Hb. The exception may be in ischemic tissue,
where nitrite could be converted to NO by protonation. Thus, the peripheral oncogenic effects
of inhaled NO could result from delivery of nitrite to ischemic tissues [76]. The peripheral
physiologic effects of inhaled NO are typically dose- and oxygen tension-dependent and can
occur without systemic hemodynamic changes [26, 77].
Nitric oxide equivalents are transferred as NO+ from deoxyhemoglobin to low molecular
weight thiols in erythrocytes [14, 78–81]. These low molecular weight S-nitrosothiols are hyp-
oxia-mimetic, signaling Hb R to T conformational change [14, 78–81]. One of these hypoxia-
mimetic effects is to increase minute ventilation [78, 82, 83]. To maintain pH, hyperventila-
tion-induced respiratory alkalosis will normally result in decreased bicarbonate levels. A
decrease in steady state bicarbonate of 0.1 to maintain steady-state pH, by Henderson-Hassel-
balch, corresponds to a decrease in steady state pCO2 of 0.5 mmHg. By Dubois, this corre-
sponds to a steady increase in minute ventilation of ~ 0.5 litres per minute at steady state pO2.
Though this normal physiology is not observed in critically ill patients who are mechanically
ventilated, we were able here, uniquely, to measure the decrease in bicarbonate associated with
excess NO-hemoglobin loading in spontaneously breathing, healthy subjects.
The iontophoresis of acetylcholine and sodium nitroprusside test the microvascular endo-
thelial-dependent and independent vasodilation, respectively [84]. Acetylcholine induces vaso-
dilation via the endothelial production of NO and prostanoids, pathways that likely participate
in enzymatic cross-talk [85]. Sodium nitroprusside reacts with tissue sulfhydryl groups to pro-
duce NO directly (NO donor) [85]. In our study, the inhalation of NO did not significantly
affect the microvascular cutaneous perfusion or the response to the iontophoresis of acetylcho-
line or sodium nitroprusside. These findings could represent that the microvascular studies
used were not sensitive and/or precise enough to detect the systemic microvascular effects of
inhaled NO, and/or the normal tissue oxygen tension of skin tissue. Another explanation
could be that inhaled NO elicits a more pronounced microvascular response in states of oxida-
tive stress, hypoxic tissues or decreased NO production than in healthy controls [74]. In fact,
Cannon III et al [40] noted that NO inhalation produced minimal effects on the forearm blood
flow; however, inhaled NO reverted the reduced forearm blood flow caused by the blockade of
NO synthesis with NG-monomethyl-L-arginine [40].
Prior investigations in healthy individuals showed that stimulation with acetylcholine aug-
mented forearm blood flow and venous nitrite [64, 86]. Although we showed no significant
changes in the microvascular studies during the inhalation of NO, we noted an inverse associa-
tion between the levels of SNO-Hb and the response to acetylcholine iontophoresis both before
and during NO administration. A higher RBC level of SNO-Hb may represent a higher NO
state with less microvascular response to the iontophoresis of acetylcholine. Interestingly, the
Nitric oxide metabolites in healthy subjects
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more pronounced the increase in SNO-Hb during NO inhalation the lower the change in
response to acetylcholine iontophoresis between baseline and NO administration.
Note that under conditions of extreme oxidative stress in the lungs, i.e. acute respiratory
distress syndrome, inhaled NO has adverse effects on renal function, whereas during heart sur-
gery without lung injury, inhaled NO may benefit renal function [28, 29]. This difference sug-
gests that airway chemistry is important to the metabolic fate and systemic effects of inhaled
NO [14] (Fig 2). Consistent with this hypothesis, SNO-Hb levels continued to increase after
the inhaled NO was discontinued. The duration of this increase was longer than a circulatory
cycle, arguing against simple transfer of NO from Fe++ Hb to Hb-thiol as the principle reason
for this steady post-dose increase [26]; and stoichiometrically, the increase in SNO-Hb
occurred without any loss of RBC NO. These data almost certainly argue for a capacitor in the
circuit: a reservoir of SNO in the airways that stores NO+ equivalents and transfers them to the
blood. In fact, airway reduced thiol levels are in excess of 100 μM, and formation of a major
SNO reservoir from endogenous thiols has previously been demonstrated in the distal airway
during NO inhalation in humans and in pigs [87, 88].
Limitations of the current study include a) a relatively small number of healthy volunteers
(n = 15) that might have prevented the identification of significant differences in microvascu-
lar studies or NO metabolites, and b) microvascular studies were not repeated after the discon-
tinuation of NO when the levels of nitrite and SNO-Hb peaked. However, for the first time, we
rigorously measured in healthy volunteers both nitrite and SNO-Hb at baseline, during and up
to 30 minutes after the discontinuation of NO inhalation. Our data show that both nitrite in
plasma and SNO-Hb in RBC increase during and immediately after NO inhalation and that
these metabolites may affect studies that test the NO pathway in the systemic
microvasculature.
Conclusions
For the first time we measured the kinetics of nitrite and SNO-Hb during NO inhalation and
after its discontinuation. Interestingly, the kinetics of these NO metabolites are not identical.
Nitrite increases first, followed by a more sustained increase in Hb-SNO, likely reflecting the
capacitor-like reservoir of SNO in the lung. Nitrite, Hb-SNO and possibly DNICs could be a
mobile reservoir of NO with implications on the systemic microvasculature.
Supporting information
S1 Table. Effect of freezing/thawing on nitrite measurements. This is a table with the mea-
surements of nitrite from samples that were fresh or frozen/thawed from a single individual.
This demonstrated that the nitrite levels were not affected by freezing and thawing under the
condition we used.
(XLSX)
S2 Table. Measurement of SNO, Nitrite, and Nitrate. This excel sheet contains the data for
the measurements of SNO, nitrite and nitrate for the different samples. It also contains the
standard curves along with the associated R2 values and the calculated values of the samples.
(XLSX)
S3 Table. Collated data for NOx metabolites, CO2 and iontophoresis related measure-
ments. In addition to the different NOx metabolites, CO2 and iontophoresis results it also
includes data related to age, gender and BMI status of the subjects.
(XLSX)
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